Dr William F Feehery is new Certara CEO

Effective 3 June, Dr William F Feehery will take over the model-informed drug development services company

Dr William F Feehery, new Certara CEO

Certara has appointed Dr William F Feehery as its new CEO and a member of the Certara Board of Directors, effective 3 June 2019.

Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a US$2.2 billion global biotechnology business which experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group.

Dr Feehery also serves as a board member for West Pharmaceutical Services, a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.

Dr Edmundo Muniz, who has served as Certara CEO since June 2014, will now become a member of the Certara Board of Directors and Chair of the Board’s newly-formed Science Committee. During Dr Muniz’ tenure as CEO, Certara has grown its model-informed decision support solutions for drug development, regulatory science and market/patient access.

“We are very pleased to welcome Bill to Certara. Bill’s broad and diverse background in technology and commercial operations position him well to lead the company. We are confident that his technical, operational and commercial expertise will serve him well as he takes the company to its next level of growth,” said Sheri McCoy, Certara Chairman of the Board. She went on to say that “we also want to thank Edmundo for the great work he has done in establishing the vision and strategy that has resulted in Certara becoming the world leader in model-informed drug development and a critical innovator in modelling and simulation.”

Dr Feehery holds both a PhD in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modelling complex systems.

Companies